High-dose pyridoxine and peripheral neuropathy: Considerations for clinicians, pharmacists and policy-makers
DOI:
https://doi.org/10.7196/SAMJ.2026.v116i5.4610Keywords:
peripheral neuropathy; pyridoxine; isoniazid; tuberculosis, medicine scheduling; regulatory; SAHPRA, South AfricaAbstract
-
References
1. Van der Watt JJ, Harrison TB, Benatar M, Heckmann JM. Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: A systematic review. Int J Tuberc Lung Dis 2011;15(6):722-728. https://doi.org/10.5588/ijtld.10.0284
2. National Department of Health, South Africa. National guidelines on the treatment of tuberculosis infection. Pretoria: NDoH, 2023.
3. Therapeutic Goods Administration, Australia. Health supplements containing vitamin B6 can cause peripheral neuropathy. Canberra: Australian Government Department of Health and Aged Care, 2022. https://www.tga.gov.au/news/safety-alerts/health-supplements-containing-vitamin-b6-can-cause- peripheral-neuropathy (accessed 19 May 2026).
4. Therapeutic Goods Administration, Australia. Safety advisory: Peripheral neuropathy from supplemental Vitamin B6 (pyridoxine). Canberra: Australian Department of Health, 2025. https://www. tga.gov.au/resources/publication/scheduling-decisions-interim/notice-interim-decision-proposed- amendments-poisons-standard-relation-pyridoxine-pyridoxal-or-pyridoxamine-vitamin-b6-acms-46- november-2024 (accessed 1 September 2025).
5. Therapeutic Goods Administration, Australia. Vitamin B6 (pyridoxine): Safety advisory – potential for dose-related adverse events. Canberra: Australian Department of Health, 2020. https://www.tga.gov.au/ safety/safety-monitoring-and-information/safety-alerts/vitamin-b6-pyridoxine (accessed 19 May 2026).
6. Turck D, Bohn T, Castenmiller J, et al. Scientific opinion on the tolerable upper intake level for vitamin B6. EFSA J 2023;21(5):e08006. https://doi.org/10.2903/j.efsa.2023.8006
7. Van Hunsel F, van de Koppel S, van Puijenbroek E, Kant A. Vitamin B6 in health supplements and neuropathy: Case series assessment of spontaneously reported cases. Drug Saf 2018;41(9):859-869. https://doi.org/10.1007/s40264-018-0664-0
8. NisarM,WatkinSW,BucknallRC,AgnewRA.Exacerbationofisoniazidinducedperipheralneuropathy by pyridoxine. Thorax 1990;45(5):419-420. https://doi.org/10.1136/thx.45.5.419
9. Therapeutic Goods Administration, Australia. Some dosages to be rescheduled as Pharmacist Only Medicines. Canberra: Australian Department of Health, 2026. https://www.tga.gov.au/news/ safety-updates/medicines-containing-vitamin-b6-pyridoxine-pyridoxal-or-pyridoxamine (accessed 19 Feb 2026).
10. Bhargava M, Bhargava A. Pyridoxine for patients suffering from drug-susceptible tuberculosis in India. Pub Health Act 2018;8(2):97. https://doi.org/10.5588/pha.18.0017
11. Hadtstein F, Vrolijk M. Vitamin B-6-induced neuropathy: Exploring the mechanisms of pyridoxine toxicity. Adv Nutr 2021;12(5):1911-1929. https://doi.org/10.1093/advances/nmab033
12. Procter & Gamble Company and affiliates. NEUROBION tablets with Vitamin B1, B6 and B12. The Procter & Gamble Company and affiliates, 2026. https://www.neurobion.com/en-za/neurobion (accessed 19 May 2026).
13. Court R, Centner CM, Chirehwa M, et al. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Int J Infect Dis 2021;105:688-694. https://doi. org/10.1016/j.ijid.2021.03.001
14. National Department of Health, South Africa. Medicines and Related Substances Act, No. 101 of 1965. Consolidated schedules. Pretoria: NDoH, 2025. https://www.sahpra.org.za/wp-content/uploads/2025/08/ Consolidated-Schedules_01-August-2025.pdf (accessed 1 September 2025).
15. Muhamad R, Akrivaki A, Papagiannopoulou G, Zavridis P, Zis P. The role of vitamin B6 in peripheral neuropathy: A systematic review. Nutrients 2023;15(13):2823. https://doi.org/10.3390/nu15132823
Downloads
Published
Issue
Section
License
Copyright (c) 2026 B Job, M Govender, T N Gengiah
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
